Difference between revisions of "Eltrombopag (Promacta)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
| + | Also known as Revolade or SB-497115-GR. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.<ref name="insert">[http://us.gsk.com/products/assets/us_promacta.pdf Eltrombopag (Promacta) package insert]</ref><ref>[ | + | Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.<ref name="insert">[http://us.gsk.com/products/assets/us_promacta.pdf Eltrombopag (Promacta) package insert]</ref><ref>[[Media:Eltrombopag.pdf | Eltrombopag (Promacta) package insert (locally hosted backup)]]</ref><ref>[http://www.promacta.com Promacta manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *Idiopathic (immune) thrombocytopenic purpura (ITP) | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://us.gsk.com/products/assets/us_promacta.pdf#page=21 Eltrombopag (Promacta) package insert pages 21-26]<ref name="insert"></ref> | ||
| + | *Brief patient counseling information can be found on [http://us.gsk.com/products/assets/us_promacta.pdf#page=19 pages 19-20 of the package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/eltrombopag-patient-drug-information Eltrombopag (Promacta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/eltrombopag-patient-drug-information Eltrombopag (Promacta) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/eltrombopag-patient-drug-information Eltrombopag (Promacta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/eltrombopag-patient-drug-information Eltrombopag (Promacta) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Hematology medications]] | ||
| + | [[Category:Hemostasis medications]] | ||
| + | [[Category:Thrombopoietin]] | ||
Revision as of 05:22, 15 October 2012
Also known as Revolade or SB-497115-GR.
General information
Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Idiopathic (immune) thrombocytopenic purpura (ITP)
Patient drug information
- Eltrombopag (Promacta) package insert pages 21-26[1]
- Brief patient counseling information can be found on pages 19-20 of the package insert[1]
- Eltrombopag (Promacta) patient drug information (UpToDate)[4]